Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.002 | 0.0026 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.4534 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.002 | 0.0026 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.4534 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.002 | 0.0026 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.4534 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.4534 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.4534 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.4534 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.0026 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.002 | 0.0026 | 0.5 |
Brugia malayi | hypothetical protein | 0.003 | 0.4534 | 0.4534 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.0026 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 1 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.4534 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.4534 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.002 | 0.0026 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.002 | 0.0026 | 0.0026 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.4534 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 10 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. Inhibitors of USP1/UAF1: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 56.2341 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.